Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

by Business Wire • 2025/07/07 • 0 Comments

GENEVA--(BUSINESS WIRE)--Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

← VIDEO: Tyrosine kinase inhibitors may help alleviate wet AMD treatment burden

Canabrava Ring offers advantages for iris expansion →

Post navigation